ADMA Biologics, Inc. (ADMA) fair value analysis
Nasdaq · Updated 2026-10-19
ADMA price how computed
Forward Fair Value verdict
UndervaluedADMA is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $10.68
- Sector
- Healthcare
- 12-month range
- $7.60–$20.38
- Market cap
- $2.39B
- From 52-week high
- -47.6%
- Shares outstanding
- 224M
- Rank in Healthcare by discount to fair value
- #97 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
ADMA Biologics, Inc. is a biopharmaceutical company that develops and distributes specialty biologics, including plasma-derived therapies and recombinant human proteins used to treat immunodeficiency and other serious conditions. The company operates primarily in the United States, focusing on the manufacturing and commercialization of products for patients with rare and serious diseases.
ADMA currently ranks #97 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $2.39B
- P/E (trailing)
- 15x
- Revenue (TTM)
- $512M
- Net margin
- 33.0%
- EPS (TTM)
- $0.71
- Gross margin
- 69.4%
- Debt / equity
- 0.50
- Revenue growth (3-yr avg)
- 28.3%
- Shares outstanding
- 224M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 72 · overbought
- 50-day average
- $9.71
- 200-day average
- $11.31
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 2 beat, 3 missed
- Quarter by quarter
- 2026-06 ▬ met (0.0%)
2026-03 ▼ miss (-15.0%)
2025-12 ▲ beat (+15.5%)
2025-09 ▬ met (0.0%)
2025-06 ▬ met (0.0%)
2025-03 ▼ miss (-35.3%)
2024-12 ▼ miss (-6.2%)
2024-09 ▲ beat (+15.4%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 3 buy · 1 hold · 0 sell (4 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $17
- Target vs last price
- +59.2%
What our data shows for ADMA
- Our model validated 10 trailing price-to-earnings windows for ADMA, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $7.60–$20.38.
- The 14-day relative strength index sits at an overbought 72.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ADMA
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ADMA news
TickrTrends' derived news-sentiment signal for ADMA is currently leaning positive, computed from recent coverage.
- ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know (zacks.com, 2026-10-08)
TickrTrends take: ADMA Biologics operates in the Healthcare sector where valuation multiples can vary significantly based on pipeline progress and revenue growth trajectories. Given TickrTrends' current assessment that ADMA is undervalued, increased investor attention to the company may warrant examination of whether market interest is beginning to reflect the valuation opportunity or if sentiment is moving ahead of fundamental reassessment. For valuation-focused investors, the key question is whether heightened attention translates into a closing of any gap between current trading levels and the company's intrinsic value drivers in the biologics space. - Stonepine Capital Management, LLC Buys Femasys Inc (FEMY) -- Shares Look 70% Undervalued on GF Value (gurufocus.com, 2026-09-04)
TickrTrends take: ADMA operates in the Healthcare sector where valuation discrepancies can present opportunities for investors focused on fundamental analysis. TickrTrends currently assesses ADMA as undervalued, suggesting the market may be pricing in less favorable assumptions than warranted by underlying metrics. In a healthcare landscape where institutional investors like Stonepine Capital are identifying significant valuation gaps in comparable companies, investors monitoring ADMA should track whether similar analytical frameworks reveal analogous pricing inefficiencies in this stock's fundamentals. - ADMA Biologics: Maybe The Bears Are Right (Rating Downgrade) (NASDAQ:ADMA) (seekingalpha.com, 2026-09-02)
TickrTrends take: ADMA Biologics has received a rating downgrade, suggesting analyst skepticism about near-term performance despite TickrTrends' undervalued designation. For valuation-focused investors, this divergence between analyst sentiment and current valuation metrics warrants closer examination of the company's fundamental drivers, particularly given its position in the competitive Healthcare sector. The downgrade introduces uncertainty about whether the undervalued assessment reflects genuine opportunity or misses emerging operational or market challenges that analysts have identified.
What people are saying
Follow the ADMA conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — ADMA's Relative Strength Index has moved from neutral territory into overbought zone this week, indicating that the stock's recent price momentum has intensified. Despite this shift in technical positioning, TickrTrends' valuation assessment maintains that the Healthcare sector company remains undervalued at current levels.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ADMA stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), ADMA is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is ADMA's TickrTrends verdict?
ADMA's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does ADMA compare to other Healthcare stocks?
ADMA ranks #97 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is ADMA overbought or oversold?
ADMA's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.
When does ADMA report earnings next?
ADMA's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does ADMA usually beat earnings estimates?
Over its last 8 reported quarters ADMA beat the consensus estimate 2 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ADMA?
Of 4 analysts covering ADMA, 3 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $17 (+59.2% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
ADMA vs ALGN · ADMA vs ANIP · ADMA vs ASND · ADMA vs ASTH · ADMA vs AZN